A combination of LB100 and the tyrosine kinase inhibitor dasatinib in a transgenic mouse model of CML has been found by Lai et al.30 to result in significantly fewer BCR-ABL transcripts than those in control mice (P < 0.01). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.